Otologic Pharmaceuticsinc Opiwas Founded In 2009 To Develop Novel Therapeutics To Prevent And Restore Hearing Lossopi Has A Clinical Stage Program For An Oral Medication For Residual Hearing Loss Protection In Cochlear Implants With Secondary Indications In Meniere S Disease And Tinnitus And Preclinical Programs Focused On The Restoration Of Hearing Function Resulting From Chronic And Age Related Hearing Losscurrentlyno Pharmacological Treatment For Hearing Loss Is Availablethe Status Of Opi S Programs Is As Follows Aecnhpn 1010Hpn 07 Plus N Acetylcysteinenaccompleted Two Phase 1 Safety Pharmacokinetic Studies In Healthy Volunteersand Is Anticipated To Enter A Phase 2 Trial In Collaboration With Oblatoaecpreclinical Sirna Program For Regeneration Of Auditory Sensory Epitheliahair Cellsin The Cochlea Lost As A Result Of Age Related Hearing Loss Or Chronic Nihlhas Demonstrated Restoration Of Auditory Function In Animal Models Of Acute And Chronic Hearing Losspress Releaseshttps Www Prnewswire Com News Releases Oblato Biotech Company Acquires Hearing Loss Drug Discovered By Hough Ear Institute Scientists 301003204 Html
No conferences found for this company.
| Company Name | Otologic Pharmaceutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
